drugset

drugset / Trial / NCT00528242

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

NCT00528242 ↗

Phase 2 Completed 17 enrolled Response Pharmaceuticals

RandomizedCrossoverDouble-blindTreatment

Summary

To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.

Timeline

Start: 2007-06
Primary completion: 2008-03
Completion: 2008-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SLx-2101	Unknown	—	Oral

Indications